Infinity Pharmaceuticals, Inc.

Pagina dedicata companiei Infinity Pharmaceuticals, Inc. listata cu simbolul US.INFI

Descriere companie

Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, (http://www.infi.com/) is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for people with cancer. It is also focusing on advancing, eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its pipeline includes MARIO-275 is, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line setting for triple negative breast cancer (TNBC), and front-line renal cell carcinoma (RCC). MARIO-1 is in Phase I /1b clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity for eganelisib.

Ultimele stiri despre Infinity Pharmaceuticals, Inc. (US.INFI)

• Infinity Pharmaceuticals, Inc.